STING Agonist Compounds for Immunotherapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for compounds that can modulate the activity of STING, particularly as STING agonists, to treat inflammatory, allergic, autoimmune, infectious diseases, cancer, and pre-cancerous syndromes, as existing treatments are inadequate in effectively activating or inhibiting type I interferon production for therapeutic benefits.
Innovation Solution
Development of compounds of formula (I) and their pharmaceutical compositions that act as STING agonists, activating STING to induce type I interferon production for immunotherapy and cancer treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments are used to activate or inhibit type I interferon production, then therapeutic benefits are limited, but the complexity and inefficacy of treatment remain high
Solution Approach 1:
The patent modifies chemical parameters by developing novel compounds with specific structural features (formula I) that optimize STING activation. By changing molecular parameters such as substituent groups R1-R6, ring structures, and linker groups Y1-Y3, the invention achieves enhanced therapeutic efficacy and selectivity for STING modulation compared to existing treatments
Solution Approach 2:
The patent creates simplified copies of the natural STING agonist 2′,3′-cGAMP through synthetic analogs. These compound copies (formula I) replicate and enhance the biological function of the natural molecule while improving pharmacological properties, thereby providing a more effective and manageable treatment option
2Strength
If STING activation is enhanced to improve immune response, then anti-tumor and anti-infectious effects are improved, but the risk of excessive interferon production and side effects increases
Solution Approach 1:
The patent applies partial action by designing compounds that provide optimal, controlled activation of STING rather than maximal activation. The compounds of formula I are engineered to achieve sufficient STING activation for therapeutic effect while avoiding overactivation, thereby balancing immune response enhancement with safety through controlled dosing and selective binding
Solution Approach 2:
The patent uses the STING protein itself as an intermediary mediator between the administered compounds and the immune system. The compounds of formula I bind to STING, which then acts as a controlled intermediary to regulate type I interferon production, preventing direct and uncontrolled activation while maintaining therapeutic efficacy through the intermediary's natural regulatory mechanisms
Data Source
AI summary
The present invention relates to compounds of formula (I) and salts, stereoisomers, tautomers or N-oxides thereof that are useful as modulators of STING (Stimulator of Interferon Genes). The present invention further relates to the compounds of formula (I) for use as a medicament and to a pharmaceutical composition comprising said compounds.